Tilly H, Castaigne S, Bordessoule D, Sigaux F, Daniel M T, Monconduit M, Degos L
Cancer. 1985 Apr 15;55(8):1633-6. doi: 10.1002/1097-0142(19850415)55:8<1633::aid-cncr2820550803>3.0.co;2-w.
Thirty patients older than 65 years of age with acute nonlymphocytic leukemia were treated with low-dose cytosine arabinoside (10 mg/m2 subcutaneously every 12 hours for 15 to 21 days). Fifteen achieved complete remission and five had partial remission. Treatment was more effective when initial bone marrow cellularity was low (P = 0.007). Four of six patients with secondary leukemia entered complete or partial remission. Therapy was well tolerated with reduced myelosuppression and few number of early deaths. Sixteen patients followed the whole treatment as outpatients. Six of 12 patients who achieved complete remission showed no evidence of post-therapeutic bone marrow aplasia. These data are consistent with the view that low-dose cytosine arabinoside acts on leukemic cells as a differentiating agent.
30例65岁以上的急性非淋巴细胞白血病患者接受了小剂量阿糖胞苷治疗（每12小时皮下注射10mg/m²，共15至21天）。15例达到完全缓解，5例部分缓解。当初始骨髓细胞计数较低时，治疗效果更佳（P = 0.007）。6例继发性白血病患者中有4例进入完全或部分缓解。该治疗耐受性良好，骨髓抑制减轻，早期死亡人数较少。16例患者作为门诊患者完成了整个治疗。12例达到完全缓解的患者中有6例未显示出治疗后骨髓再生障碍的迹象。这些数据与小剂量阿糖胞苷作为分化剂作用于白血病细胞的观点一致。
